Global Information
회사소개 | 문의 | 위시리스트

자궁근종(자궁종양) : 파이프라인 리뷰

Uterine Leiomyoma (Uterine Fibroids) - Pipeline Review, H1 2020

리서치사 Global Markets Direct
발행일 2020년 01월 상품 코드 912072
페이지 정보 영문 113 Pages
가격
US $ 2,000 ₩ 2,435,000 PDF by E-mail (Single User License) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,870,000 PDF by E-mail (Site License) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,000 ₩ 7,305,000 PDF by E-mail (Global License) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


자궁근종(자궁종양) : 파이프라인 리뷰 Uterine Leiomyoma (Uterine Fibroids) - Pipeline Review, H1 2020
발행일 : 2020년 01월 페이지 정보 : 영문 113 Pages

세계 각국의 자궁근종(자궁종양) 치료용 파이프라인 제품 개발 상황에 대해 분석했으며, 파이프라인 제품의 최신 동향, 임상시험 단계별 제품 리스트, 주요 기업 개요, 주요 약제 개요, 최신 업계 동향 등을 조사했습니다.

서론

  • 조사 범위

자궁근종(자궁종양) - 개요

자궁근종(자궁종양) - 치료제 개발

  • 파이프라인 개요
  • 기업별 파이프라인 동향
  • 대학 및 연구기관별 파이프라인 동향
  • 기업에서 개발중인 제품
  • 대학 및 연구기관에서 개발중인 제품

자궁근종(자궁종양) - 치료제 평가

  • 표적별
  • 작용기전별
  • 투여 경로별
  • 분자 종류별

자궁근종(자궁종양) 치료제 개발에 참여하고 있는 기업

  • AbbVie Inc
  • Addex Therapeutics Ltd
  • Auritec Pharmaceuticals Inc
  • Bayer AG
  • BioSpecifics Technologies Corp
  • GeneScience Pharmaceuticals Co Ltd
  • Immunitor Inc
  • Kissei Pharmaceutical Co Ltd
  • Livzon Pharmaceutical Group Co Ltd
  • Luye Pharma Group Ltd
  • Richter Gedeon Nyrt
  • Takeda Pharmaceutical Co Ltd

약제 개요

자궁근종(자궁종양) - 휴지 상태인 프로젝트

자궁근종(자궁종양) - 개발이 중지된 제품

자궁근종(자궁종양) - 제품 개발 마일스톤

  • 주요 뉴스와 프레스 릴리스

부록

LSH 19.10.01

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

List of Tables

  • Number of Products under Development for Uterine Leiomyoma (Uterine Fibroids), H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Uterine Leiomyoma (Uterine Fibroids) - Pipeline by AbbVie Inc, H1 2020
  • Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Auritec Pharmaceuticals Inc, H1 2020
  • Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Bayer AG, H1 2020
  • Uterine Leiomyoma (Uterine Fibroids) - Pipeline by BioSpecifics Technologies Corp, H1 2020
  • Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Context Therapeutics LLC, H1 2020
  • Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Evestra Inc, H1 2020
  • Uterine Leiomyoma (Uterine Fibroids) - Pipeline by GeneScience Pharmaceuticals Co Ltd, H1 2020
  • Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Immunitor Inc, H1 2020
  • Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Kissei Pharmaceutical Co Ltd, H1 2020
  • Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Livzon Pharmaceutical Group Co Ltd, H1 2020
  • Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Luye Pharma Group Ltd, H1 2020
  • Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Richter Gedeon Nyrt, H1 2020
  • Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Takeda Pharmaceutical Co Ltd, H1 2020
  • Uterine Leiomyoma (Uterine Fibroids) - Pipeline by TiumBio Co Ltd, H1 2020
  • Uterine Leiomyoma (Uterine Fibroids) - Dormant Projects, H1 2020
  • Uterine Leiomyoma (Uterine Fibroids) - Dormant Projects, H1 2020 (Contd..1), H1 2020
  • Uterine Leiomyoma (Uterine Fibroids) - Discontinued Products, H1 2020

List of Figures

  • Number of Products under Development for Uterine Leiomyoma (Uterine Fibroids), H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products by Targets, H1 2020
  • Number of Products by Stage and Targets, H1 2020
  • Number of Products by Mechanism of Actions, H1 2020
  • Number of Products by Stage and Mechanism of Actions, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Molecule Types, H1 2020
  • Number of Products by Stage and Molecule Types, H1 2020

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Uterine Leiomyoma (Uterine Fibroids) - Pipeline Review, H1 2020, provides an overview of the Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders) pipeline landscape.

Uterine fibroids are benign tumors that originate in the uterus (womb). Although they are composed of the same smooth muscle fibers as the uterine wall (myometrium), they are much denser than normal myometrium. Uterine fibroids are usually round. The most common symptoms of uterine fibroids include heavy menstrual bleeding, prolonged menstrual periods seven days or more of menstrual bleeding, pelvic pressure or pain, frequent urination, difficulty emptying bladder, constipation and backache or leg pains.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Uterine Leiomyoma (Uterine Fibroids) - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders) pipeline guide also reviews of key players involved in therapeutic development for Uterine Leiomyoma (Uterine Fibroids) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Unknown stages are 2, 3, 1, 3, 4 and 1 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders).
  • The pipeline guide reviews pipeline therapeutics for Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Introduction

  • Uterine Leiomyoma (Uterine Fibroids) - Overview
  • Uterine Leiomyoma (Uterine Fibroids) - Therapeutics Development
  • Uterine Leiomyoma (Uterine Fibroids) - Therapeutics Assessment
  • Uterine Leiomyoma (Uterine Fibroids) - Companies Involved in Therapeutics Development
  • Uterine Leiomyoma (Uterine Fibroids) - Drug Profiles
  • Uterine Leiomyoma (Uterine Fibroids) - Dormant Projects
  • Uterine Leiomyoma (Uterine Fibroids) - Discontinued Products
  • Uterine Leiomyoma (Uterine Fibroids) - Product Development Milestones
  • Appendix
Back to Top
전화 문의
F A Q